Inflammatory Bowel Diseases最新文献

{"title":"Incidence of acne in patients with inflammatory bowel disease treated with Janus kinase inhibitors: a systematic review and meta-analysis.","authors":"Mohammed Nabil Quraishi, Maryam A Alahmad, Thaer Khaleel Swaid, Antonio Facciorusso, Alyssa A Grimshaw, Badr Al-Bawardy","doi":"10.1093/ibd/izag032","DOIUrl":"10.1093/ibd/izag032","url":null,"abstract":"<p><strong>Background: </strong>Janus kinase (JAK) inhibitors are effective oral therapies for inflammatory bowel disease (IBD). While acne is a known adverse event in dermatological cohorts, its incidence and risk factors in the IBD population are not well-defined. We aimed to determine the pooled incidence of acne in IBD patients treated with JAK inhibitors and to explore this risk across key clinical subgroups.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis following PRISMA guidelines. MEDLINE, EMBASE, and CENTRAL were searched from inception to September 2025 for randomized controlled trials (RCTs) and observational studies reporting acne incidence in IBD patients on JAK inhibitors. Data were pooled using a random-effects generalized linear mixed-effects model. Pre-specified subgroup analyses were performed.</p><p><strong>Results: </strong>A total of 50 studies (5 RCTs, 45 observational) involving 9902 IBD patients were included. The overall pooled incidence of acne was 8.6% (95% CI: 6.4%-11.6%). Acne rates were significantly higher (P < .0001) with the upadacitinib (12.2%), compared to tofacitinib (2.6%) and filgotinib (2.3%). A numerically higher incidence was observed during induction (8.6%) versus maintenance (4.2%) therapy, though this difference was not statistically significant (P = .07). The incidence was significantly higher in the pediatric population (12.2%) compared to adults (7.4%) (P = .03). In RCTs, JAK inhibitors were associated with significantly increased odds of acne compared to placebo (OR 2.43, 95% CI: 1.33-4.43, P = .019). No statistically significant difference was observed by IBD subtype.</p><p><strong>Conclusion: </strong>Acne is a common adverse event in IBD patients treated with JAK inhibitors. The reported incidence of acne was significantly higher with upadacitinib, in the pediatric population, and numerically higher during the induction phase of treatment.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1800-1814"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147354820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging-based prediction of biologic failure in perianal Crohn's disease: the emerging role of 3D transrectal ultrasound.","authors":"Zeinab Bakhshi, Ritika Kumari, Jalpa Devi","doi":"10.1093/ibd/izag125","DOIUrl":"10.1093/ibd/izag125","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1859-1861"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148294912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mast cell-derived IL-13 as a driver of Crohn disease-associated intestinal fibrosis.","authors":"Kwestan Safari, Wei Jen Ma, Prabhreet Sekhon, Priya Rai, Susan C Menzies, Tomoaki Hoshino, Anne-Sophie Fratzscher, Andrew Roth, Karen Madsen, Laura M Sly","doi":"10.1093/ibd/izag127","DOIUrl":"10.1093/ibd/izag127","url":null,"abstract":"<p><strong>Background: </strong>Crohn disease is a chronic, immune-mediated disease that can lead to intestinal fibrosis, strictures, and bowel obstruction. The Src homology 2 domain-containing inositol polyphosphate 5'-phosphatase-deficient (SHIP-/-) mouse develops spontaneous Crohn disease-like ileal inflammation and fibrosis. Fibrosis depends on increased phosphatidylinositol 3-kinase p110δ activity downstream of interleukin 4 (IL-4) or IL-13. Because current anti-inflammatory treatments do not prevent or reverse fibrosis, we aimed to identify the key cytokine(s) and its cellular source(s).</p><p><strong>Methods: </strong>We blocked IL-4 or IL-13 in mice by use of neutralizing antibodies or genetic ablation. Intestinal inflammation and fibrosis were assessed by gross pathology, histopathology, collagen accumulation, muscle thickening, immune cell infiltration, and tissue IL-1β concentrations. IL13 and its cellular source in stricturing Crohn disease were examined using single-cell RNA sequencing and RNAscope. Mast cells and Il13 were also assessed in ileal cross-sections from SHIP+/+ and SHIP-/- mice.</p><p><strong>Results: </strong>Blocking or genetic ablation of IL-13, but not IL-4, significantly reduced ileal fibrosis in mice, including collagen accumulation, smooth muscle thickening, vimentin + cells, and proliferating vimentin + cells. Blockade of IL-13 also reduced intestinal inflammation, including immune cell infiltration and ileal IL-1β concentrations. Single-cell RNA-sequencing analyses identified mast cells as the exclusive source of IL13 in stricturing Crohn disease. Human resection tissues confirmed increased mast cells in diseased small intestine and identified mast cells as the source of IL13. SHIP-/- mice similarly showed increased ileal mast cells that were also a source of IL13.</p><p><strong>Conclusions: </strong>IL-13 is critical for intestinal fibrosis in SHIP-deficient mice, and mast cells are a source of IL13 in Crohn disease-associated intestinal fibrosis.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1783-1799"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13533194/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148411604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prevalence of abdominal computed tomography imaging findings in patients with inflammatory bowel disease who present to the emergency department: a systematic review and meta-analysis.","authors":"Althaf Azward, Gabriella Ripstein, Edgard Medawar, Sanjay Murthy, Blair Macdonald, Hans Rosenberg, Cynthia H Seow, Siddharth Singh, Jeffrey D McCurdy","doi":"10.1093/ibd/izag053","DOIUrl":"10.1093/ibd/izag053","url":null,"abstract":"<p><strong>Background: </strong>The diagnostic yield of abdominal computed tomographic (CT) imaging for patients with inflammatory bowel disease (IBD) in the emergency department (ED) is unclear. We aimed to estimate the prevalence of IBD and non-IBD pathologies detected by CT imaging in the ED.</p><p><strong>Methods: </strong>Multiple databases were systematically searched from inception until April 18, 2025. We included studies that reported abdominal CT findings among IBD patients in the ED. We estimated the prevalence of IBD and non-IBD findings using weighted proportions with 95% confidence intervals (CI). IBD-related findings were reported separately for Crohns disease (CD) and ulcerative colitis (UC), whereas non-IBD findings were pooled for both IBD subtypes.</p><p><strong>Results: </strong>Overall, 19 studies were analyzed. Among patients with CD (15 studies; n = 7681 CT scans) and UC (7 studies; n = 858 CT scans), the pooled prevalence of penetrating IBD findings were low: abscesses/inflammatory masses [CD, 12% (95% CI, 10-14); UC, 3% (95% CI, 1-6)] and perforations [CD, 3% (95% CI, 2-4); UC, 1% (95% CI, 0-2)]. Rates of other IBD findings included: inflammation [CD, 43% (95% CI, 30-57); UC, 48% (95% CI, 31-65)] and obstructions [CD, 18% (95% CI, 13-23); UC, 9% (95% CI, 1-20)]. Non-IBD pathologies were uncommon: less than 5% each for pulmonary, non-IBD gastrointestinal, or genitourinary findings.</p><p><strong>Conclusion: </strong>In this meta-analysis, we found low rates of serious penetrating IBD complications and non-IBD pathologies detected by abdominal CT in the ED. These findings suggest that more selective use of CT imaging in the ED may be warranted.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1722-1730"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147716884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editor: GLP‑1RAs for pouchitis in obesity: what the current study does not tell us.","authors":"Zhengwen Zhu, Huazhen Lai, Lu Chen","doi":"10.1093/ibd/izag133","DOIUrl":"10.1093/ibd/izag133","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1866-1867"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148420897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolome remodeling with reverse-engineered exclusive enteral nutrition in children with active Crohn's disease.","authors":"David L Suskind, Lucas R Hoffman, Dale Lee, Adrian J Verster, Hengqi Betty Zheng, Kendra Francis, Mason Nuding, Jairam Vanamala, Ghassan Wahbeh, Hayley Purcell, Danijel Djukovic, Daniel Raftery, Hillary S Hayden","doi":"10.1093/ibd/izag095","DOIUrl":"10.1093/ibd/izag095","url":null,"abstract":"<p><strong>Background: </strong>For children with Crohn's disease (CD), dietary therapy with exclusive enteral nutrition (EEN) is effective in achieving clinical and biochemical remission. We investigated changes in metabolites in multiple clinical sample types from children with CD following a whole foods-blended (\"reverse-engineered\") EEN formula and defined associations between these changes and remission.</p><p><strong>Methods: </strong>Stool, urine, serum, and plasma from a prospective study of newly diagnosed pediatric patients with CD enrolled in a 4-week trial of reverse-engineered exclusive enteral nutrition (RE-EEN) were analyzed using mass spectrometry targeting aqueous metabolites, bile acids, and short-chain fatty acids. Principal component analysis, mixed-effects models, and exploratory multivariate approaches including random forest and partial least-squares discriminant analysis were used to identify patterns associated with diet and metabolite abundances.</p><p><strong>Results: </strong>Fecal, urine, serum, and plasma metabolomes changed significantly during RE-EEN treatment from baseline. These global changes were largely driven by increases in amino acids and related metabolites and decreases in different amino acids and metabolites reflecting carbohydrate and purine metabolism, in all sample types. While global bile acid profiles changed with the RE-EEN diet, no changes in specific bile acid levels reached significance, and no changes were found in short-chain fatty acid concentrations.</p><p><strong>Conclusion: </strong>Metabolomic profiles for pediatric patients with CD changed broadly during RE-EEN, indicating that this therapy may modulate key systemic and gut-associated metabolic processes. The findings further suggest that the gut metabolic processes influenced by RE-EEN, and that contribute to clinical improvement, may differ from those impacted by commercial EEN diets. Further research is crucial to validate these findings, uncover causal relationships, and optimize dietary protocols to enhance therapeutic outcomes in CD.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1683-1694"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13533203/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148411636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extraintestinal manifestations in Korean patients with inflammatory bowel disease: A nationwide population-based study from 2005 to 2017.","authors":"Sung Sil Park, Yun Jin Kim, Byung Kyu Ahn","doi":"10.1093/ibd/izag068","DOIUrl":"10.1093/ibd/izag068","url":null,"abstract":"<p><strong>Background: </strong>Extraintestinal manifestations (EIMs) significantly contribute to morbidity in individuals with inflammatory bowel disease (IBD); however, population-based East Asian data remain limited. We evaluated EIM burden in a nationwide Korean IBD cohort.</p><p><strong>Methods: </strong>This nationwide retrospective cohort study was conducted using data from the Korean National Health Insurance Service between 2005 and 2017. Individuals with ulcerative colitis (UC) or Crohn's disease (CD) were identified using the International Classification of Diseases-10th Edition and rare intractable disease codes. EIM incidence, associated risk factors, interval from IBD diagnosis to EIM onset, and trends by sex and age were examined.</p><p><strong>Results: </strong>Among 69 414 individuals with IBD (48 689 UC, 20 725 CD), 42.23% developed at least 1 EIM. Dermatologic manifestations were the most common (17.02%), followed by musculoskeletal (16.36%), hepatopancreaticobiliary (15.48%), and ophthalmologic (7.83%) manifestations. Low socioeconomic status, smoking history, female sex, and higher Charlson Comorbidity Index scores independently correlated with EIM development in UC (hazard ratios of 2.14, 1.18, 1.15, and 1.08, respectively) and CD (hazard ratios of 1.98, 1.20, 1.18, and 1.09, respectively). Most EIMs developed within 4 to 6 years postdiagnosis, with musculoskeletal EIMs occurring earliest (median 42.9 months [interquartile range: 10.3-89.5 months]). Annual EIM incidence increased steadily over time across all age groups.</p><p><strong>Conclusions: </strong>EIMs affected 42.23% of Korean individuals with IBD, most frequently appearing 4 to 6 years postdiagnosis. Low socioeconomic status, smoking history, female sex, and higher Charlson Comorbidity Index scores consistently correlated with EIM occurrence, and incidence increased steadily over time, highlighting the need for sustained, personalized monitoring and timely intervention.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1760-1769"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147814080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interpreting oral dysbiosis during nutritional therapy in pediatric Crohn disease.","authors":"Huan Xu, Tongdong Zeng, Wen Wang","doi":"10.1093/ibd/izag149","DOIUrl":"10.1093/ibd/izag149","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1864-1865"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148602521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the editors.","authors":"Michael Doulberis, Stergios A Polyzos, Abbas Yadegar, Jannis Kountouras","doi":"10.1093/ibd/izag129","DOIUrl":"10.1093/ibd/izag129","url":null,"abstract":"","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1857-1858"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148328916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disentangling the gut microbiome and inflammation in inflammatory bowel diseases: longitudinal observations from the IBSEN III study.","authors":"Maria G Maseng, Simen H Hansen, Olle Grännö, Corinna Bang, Charlotte Lund, Gert Huppertz-Hauss, Gøri Perminow, Jørgen Valeur, May-Bente Bengtson, Randi Opheim, Raziye Boyar, Svein O Frigstad, Tone Bergene Aabrekk, Trond Espen Detlie, Vendel A Kristensen, Vibeke Strande, Øistein Hovde, Øyvind Asak, Andre Franke, Jonas Halfvarsson, Marte L Høivik, Johannes R Hov","doi":"10.1093/ibd/izag051","DOIUrl":"10.1093/ibd/izag051","url":null,"abstract":"<p><strong>Background and aim: </strong>Despite the well-established involvement of the gut microbiome in inflammatory bowel disease (IBD), less is known about how the gut microbiome changes over time and how it varies with clinical disease activity and fecal calprotectin (f-calprotectin). To address this gap, we utilized samples from the population-based inception cohort of the Inflammatory Bowel Disease in South-Eastern Norway III (IBSEN III) study.</p><p><strong>Methods: </strong>Data and stool samples from study participants with IBD and symptomatic controls were collected at diagnosis and after 3, 6, and 12 months. Microbiome profiling of stool samples was performed targeting the V3-V4 region of the 16S rRNA gene, and a consensus-based approach of mixed models was employed for the longitudinal microbiome analysis.</p><p><strong>Results: </strong>We included 1251 samples from 744 patients with ulcerative colitis, 618 samples from 356 patients with Crohn' s disease and 266 samples from 164 symptomatic non-IBD controls. In the IBD population, we observed that levels of f-calprotectin decreased over time, as did the patient-reported disease activity (P < .001). Distinct changes in the gut microbiome of IBD patients were observed throughout the first year, such as increased alpha diversity (P < .001) and significant taxonomic changes.Notably, there was no covariation between the changes in alpha diversity and f-calprotectin or symptom score.</p><p><strong>Conclusion: </strong>The gut microbiome during the first year after IBD diagnosis showed changes that paralleled inflammation and clinical disease activity, albeit without covariation, suggesting that there may be a disease-driving impact of gut microbiome independent of inflammation and inflammation-driven symptoms.</p>","PeriodicalId":13623,"journal":{"name":"Inflammatory Bowel Diseases","volume":" ","pages":"1695-1706"},"PeriodicalIF":5.5,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13533192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147672859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}